Can I continue to take slow-grained dasatinib after interferon resistance is restored?

For patients with chronic myelogenous leukemia (CML), if drug resistance develops after taking dasatinib and their condition improves after trying interferon (IFN), whether they can continue to take dasatinib or interferon needs to be decided based on the patient's specific situation and the doctor's advice.

When resistance to dasatinib develops, it usually means that the drug's ability to control the disease is diminished or lost. At this time, the treatment plan needs to be adjusted in time to avoid further deterioration of the condition.

Relevant examinations such as pathological biopsy and genetic testing can be performed to clarify the specific causes of drug resistance and genetic mutations. According to the examination results, under the guidance of a doctor, the patient may be switched to other potentially effective drugs, such as nilotinib, bosutinib, etc. If monotherapy is ineffective, a combination of two or more targeted drugs may be considered to enhance the therapeutic effect. In certain cases, your doctor may recommend increasing the dose of the medication or prolonging the treatment to see if there is improvement.

Interferon also has certain applications inCML treatment, but it is usually not the drug of choice. When resistance to dasatinib occurs, if the doctor recommends the use of interferon and the condition improves after use, then you can consider continuing to use the drug.

During the use of interferon, the patient's blood routine, liver and kidney function, and disease-related indicators need to be closely monitored to evaluate the therapeutic effect and safety. Interferon may cause some side effects, such as fever, flu-like symptoms, bone marrow suppression, etc. During use, it is necessary to pay close attention to the patient's physical condition and deal with side effects in a timely manner. The doctor will comprehensively evaluate whether to continue using interferon or adjust the treatment plan based on the patient's overall condition (including age, physical condition, treatment response, etc.).